Anti Inflammatory Peptides Market Size, Share, Analysis 2030
Anti Inflammatory Peptides Market Size, Share, Analysis 2030
Segments - Anti-inflammatory Peptides Market by Applications (Gastrointestinal Diseases, Cardiovascular Diseases, Neurological Diseases, Dermatological Diseases, Ophthalmological & Orthino Diseases, Renal Diseases, Transplantation, Respiratory Diseases & Pulmonary, and Rheumatological & Autoimmune Diseases) and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021-2028
Upcoming
| Report ID :HC-2525
| 4.6 Rating
| 76 Reviews
| 200 Pages
| Format :
Report Description
The global anti-inflammatory peptides market size is estimated to register a considerable CAGR during the forecast period, 2021-2028. The growth of the market is attributed to the rising prevalence of disorders including psoriasis, multiple sclerosis, autoimmune diseases, and inflammatory bowel diseases.
Increasing awareness among patients regarding the timely treatment of such disorders is another key factor driving the market growth.
Anti-inflammatory peptides are small but useful elements that suppress or slow down the inflammation of a mammal’s skin, mucous membranes, and injury in the lungs’ air spaces. As per the reports by the World Psoriasis Day Consortium, approximately 130 million people are affected by this disease globally which is about 3% to 4% of the total population. One of the reports by the World Health Organization (WHO) states that about 30 out of 100,000 individuals are affected by multiple sclerosis. The two major inflammatory bowel diseases that are most common are ulcerative colitis and Crohn’s disease as their prevalence are more in the urban areas as compared to rural areas.
Market Trends, Drivers, Restraints, and Opportunities
- Increasing geriatric population base leads to weakening of natural immunity in the direction of the pro-inflammatory status of the human body, which is expected to drive the market growth.
- Adoption of unhealthy lifestyle among a large number of the global population coupled with increasing obesity among them are expected to propel the market during the forecast period.
- Presence of advanced and well-established healthcare infrastructures in the developed regions is anticipated to drive the market expansion in the coming years.
- Expiration of patents of branded drugs coupled with side-effects caused due to anti-inflammatory drugs are key challenges that can hamper the market growth.
- Ongoing research to discover new and effective anti-inflammatory peptides is projected to create lucrative opportunities for market growth during the forecast period.
Scope of the Report
The report on the global anti-inflammatory peptides market includes an assessment of the market, trends, and segments. Overview and dynamics have also been included in the report.
|
Attributes |
Details |
|
Report Title |
Anti-inflammatory Peptides Market – Global Industry Analysis, Growth, Share, Size, Trends, And Forecast |
|
Base Year |
2020 |
|
Historic Data |
2018–2019 |
|
Forecast Period |
2021–2028 |
|
Segmentation |
Applications (Gastrointestinal Diseases, Cardiovascular Diseases, Neurological Diseases, Dermatological Diseases, Ophthalmological & Orthino Diseases, Renal Diseases, Transplantation, Respiratory Diseases & Pulmonary, and Rheumatological & Autoimmune Diseases) |
|
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
|
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
|
Key Players Covered in the Report |
Abbvie Corp.; Novartis AG; Merck Serono; Rogne Bioscience; F4 Pharma; Digna Biotech; Araim Pharmaceuticals, Inc.; and Mylan Pharmaceuticals |
Market Segment Insights
Cardiovascular diseases segment is expected to dominate the market
On the basis of applications, the global anti-inflammatory peptides market is segmented into gastrointestinal diseases, cardiovascular diseases, neurological diseases, dermatological diseases, ophthalmological & orthino diseases, renal diseases, transplantation, respiratory diseases & pulmonary, and rheumatological & autoimmune diseases. Among all the segments, the cardiovascular diseases segment held a major share of the market in 2019 and is expected to dominate the market during the forecast period. The segment growth is attributed to the global increasing incidence of cardiovascular diseases among a large number of the global population.
Asia Pacific is anticipated to expand at a lucrative growth rate
In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America accounted for a key share of the market in 2019 and is projected to constitute a considerable market share during the projected period attributed to the presence of strong research & development, technologically advanced systems, and high awareness levels among the patients in the region. Moreover, other factor contributing to the segment growth is due to the increasing prevalence of psoriasis and multiple sclerosis. As per the survey in 2013 by the National Psoriasis Foundation, approximately 7.6 million individuals are affected with psoriasis and 400,000 new cases were registered in the same year in the U.S.
On the other hand, the market in Latin America is also expected to witness a healthy growth rate in the coming years due to the rise of public and private associations, which leads to an increase in investment in the market. However, the market of Asia Pacific is anticipated to expand at a lucrative growth rate during the projected period attributed to the improvement of healthcare infrastructure at a fast pace in the region. Some other major factors driving the market expansion are the increasing level of awareness among patients and the rise in the number of patients in the region.
Segments
The global anti-inflammatory peptides market has been segmented on the basis of
Applications
- Gastrointestinal Diseases
- Cardiovascular Diseases
- Neurological Diseases
- Dermatological Diseases
- Ophthalmological & Orthino Diseases
- Renal Diseases
- Transplantation
- Respiratory Diseases & Pulmonary
- Rheumatological & Autoimmune Diseases
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Abbvie Corp.
- Novartis AG
- Merck Serono
- Rogne Bioscience
- F4 Pharma
- Digna Biotech
- Araim Pharmaceuticals, Inc.
- Mylan Pharmaceuticals
Competitive Landscape
Key players competing in the global anti-inflammatory peptides market are Abbvie Corp.; Novartis AG; Merck Serono; Rogne Bioscience; F4 Pharma; Digna Biotech; Araim Pharmaceuticals, Inc.; and Mylan Pharmaceuticals. Many of these players have adopted business strategies such as development of novel drugs, launch of new products, technology advancement, partnerships, mergers, and production capacity expansion in order to increase their expansion, their consumer base, and market position globally.
Table Of Content
1. Executive Summary2. Assumptions and Acronyms Used
3. Research Methodology
4. Anti-inflammatory Peptides Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Anti-inflammatory Peptides Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Anti-inflammatory Peptides Market - Supply Chain
4.5. Global Anti-inflammatory Peptides Market Forecast
4.5.1. Anti-inflammatory Peptides Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Anti-inflammatory Peptides Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Anti-inflammatory Peptides Market Absolute $ Opportunity
5. Global Anti-inflammatory Peptides Market Analysis and Forecast by Region
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Region
5.2.2. Y-o-Y Growth Projections by Region
5.3. Anti-inflammatory Peptides Market Size and Volume Forecast by Region
5.3.1. North America
5.3.2. Latin America
5.3.3. Europe
5.3.4. Asia Pacific
5.3.5. Middle East and Africa (MEA)
5.4. Absolute $ Opportunity Assessment by Region
5.5. Market Attractiveness/Growth Potential Analysis by Region
5.6. Global Anti-inflammatory Peptides Demand Share Forecast, 2019-2026
6. North America Anti-inflammatory Peptides Market Analysis and Forecast
6.1. Introduction
6.1.1. Basis Point Share (BPS) Analysis by Country
6.1.2. Y-o-Y Growth Projections by Country
6.2. North America Anti-inflammatory Peptides Market Size and Volume Forecast by Country
6.2.1. U.S.
6.2.2. Canada
6.3. Absolute $ Opportunity Assessment by Country
6.4. Market Attractiveness/Growth Potential Analysis
6.4.1. By Country
6.4.2. By Product Type
6.4.3. By Application
6.5. North America Anti-inflammatory Peptides Demand Share Forecast, 2019-2026
7. Latin America Anti-inflammatory Peptides Market Analysis and Forecast
7.1. Introduction
7.1.1. Basis Point Share (BPS) Analysis by Country
7.1.2. Y-o-Y Growth Projections by Country
7.1.3. Latin America Average Pricing Analysis
7.2. Latin America Anti-inflammatory Peptides Market Size and Volume Forecast by Country
7.2.1. Brazil
7.2.2. Mexico
7.2.3. Rest of Latin America
7.3. Absolute $ Opportunity Assessment by Country
7.4. Market Attractiveness/Growth Potential Analysis
7.4.1. By Country
7.4.2. By Product Type
7.4.3. By Application
7.5. Latin America Anti-inflammatory Peptides Demand Share Forecast, 2019-2026
8. Europe Anti-inflammatory Peptides Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.1.3. Europe Average Pricing Analysis
8.2. Europe Anti-inflammatory Peptides Market Size and Volume Forecast by Country
8.2.1. Germany
8.2.2. France
8.2.3. Italy
8.2.4. U.K.
8.2.5. Spain
8.2.6. Russia
8.2.7. Rest of Europe
8.3. Absolute $ Opportunity Assessment by Country
8.4. Market Attractiveness/Growth Potential Analysis
8.4.1. By Country
8.4.2. By Product Type
8.4.3. By Application
8.5. Europe Anti-inflammatory Peptides Demand Share Forecast, 2019-2026
9. Asia Pacific Anti-inflammatory Peptides Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Asia Pacific Average Pricing Analysis
9.2. Asia Pacific Anti-inflammatory Peptides Market Size and Volume Forecast by Country
9.2.1. China
9.2.2. Japan
9.2.3. South Korea
9.2.4. India
9.2.5. Australia
9.2.6. Rest of Asia Pacific (APAC)
9.3. Absolute $ Opportunity Assessment by Country
9.4. Market Attractiveness/Growth Potential Analysis
9.4.1. By Country
9.4.2. By Product Type
9.4.3. By Application
9.5. Asia Pacific Anti-inflammatory Peptides Demand Share Forecast, 2019-2026
10. Middle East & Africa Anti-inflammatory Peptides Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Middle East & Africa Average Pricing Analysis
10.2. Middle East & Africa Anti-inflammatory Peptides Market Size and Volume Forecast by Country
10.2.1. Saudi Arabia
10.2.2. South Africa
10.2.3. UAE
10.2.4. Rest of Middle East & Africa (MEA)
10.3. Absolute $ Opportunity Assessment by Country
10.4. Market Attractiveness/Growth Potential Analysis
10.4.1. By Country
10.4.2. By Product Type
10.4.3. By Application
10.5. Middle East & Africa Anti-inflammatory Peptides Demand Share Forecast, 2019-2026
11. Competition Landscape
11.1. Global Anti-inflammatory Peptides Market: Market Share Analysis
11.2. Anti-inflammatory Peptides Distributors and Customers
11.3. Anti-inflammatory Peptides Market: Competitive Dashboard
11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
Methodology
Related Reports
Some other reports from this category!
Our Clients
